Mergers & Acquisitions ·
On July 14, 2026, XOMA Royalty Corporation consummated a merger with Ligand Pharmaceuticals Incorporated
XOMAXOMA Royalty Corp
On July 14, 2026, XOMA Royalty Corporation consummated a merger with Ligand Pharmaceuticals Incorporated. Common stockholders received $39.00 per share in cash plus contingent value rights (CVRs) representing an interest in XOMA Royalty LLC. The company's 8.625% Series A and 8.375% Series B Cumulative Perpetual Preferred Stock were redeemed, including all accrued and unpaid dividends. In connection with the closing, the company terminated its Loan Agreement dated December 15, 2023, with all outstanding obligations discharged. The company has requested that Nasdaq delist and deregister its common stock. The board of directors was reconstituted, with Todd C. Davis, Octavio Espinoza, and Andrew Reardon appointed as directors. XOMA Royalty operates in the biopharmaceutical industry, managing royalty interests in pharmaceutical products.